Sign In
Buy GCTK
$0.665
+0.0044 (+0.666%)
At Close: Jun 03, 2026
Glucotrack Announces Ethical Approval for Long-Term Clinical Study of Continuous Blood Glucose Monitor
08:01am, Tuesday, 13'th May 2025
Long-term clinical evaluation represents key advancement following successful first-in-human study Long-term clinical evaluation represents key advancement following successful first-in-human study
Glucotrack to Participate in FORGETDIABETES, a Prominent European Research Initiative to Develop a Bionic Pancreas
08:00am, Wednesday, 16'th Apr 2025
RUTHERFORD, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the design, development, and commercia
Glucotrack and OneTwo Analytics to Collaborate for Clinical Study Analysis on Its Continuous Blood Glucose Monitor
08:01am, Thursday, 03'rd Apr 2025
Next Generation AI-Driven Analytics to Unlock Key Insights from the Ongoing Continuous Blood Glucose Monitoring Clinical Study Data Next Generation AI-Driven Analytics to Unlock Key Insights from the
Glucotrack Reports Full Year 2024 Financial Results and Recent Corporate Highlights
05:00pm, Monday, 31'st Mar 2025
Transformational 2024: successfully advanced from preclinical to clinical stage company Strengthened leadership team to drive growth and advance clinical development Investigational Device Exemption (
Safety and performance data from direct blood glucose measurement technology to be featured at international diabetes technology conference Safety and performance data from direct blood glucose measur
Glucotrack Appoints Guillermo Umpierrez, MD, CDCES, FACE, MACP as New Medical Advisory Board Member
08:01am, Wednesday, 26'th Feb 2025
Leading diabetes researcher and clinician joins Glucotrack as Company advances development of long-term implantable blood glucose monitoring technology Leading diabetes researcher and clinician joins
Glucotrack, Inc. Announces Pricing of $3.0 Million Public Offering
12:24pm, Tuesday, 04'th Feb 2025
Rutherford, NJ., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical technology company focused on the design, development, and commercialization of novel technologies for peo
Glucotrack Announces Successful Completion of Its First Human Clinical Study of Continuous Blood Glucose Monitor
08:01am, Tuesday, 04'th Feb 2025
The study met its primary endpoint with no procedure or device related serious adverse events reported The study met its primary endpoint with no procedure or device related serious adverse events rep
Glucotrack Strengthens Leadership Team with Appointment of New Chief Financial Officer
09:00am, Wednesday, 29'th Jan 2025
Industry veteran Peter C. Wulff joins Glucotrack to drive financial strategy and commercialization of its continuous blood glucose monitor for people with diabetes Industry veteran Peter C. Wulff join
Glucotrack Announces ISO 13485:2016 Certification
08:01am, Tuesday, 21'st Jan 2025
ISO Certification highlights commitment to quality for continuous blood glucose monitor ISO Certification highlights commitment to quality for continuous blood glucose monitor
Glucotrack Strenghtens Leadership Team with Addition of Industry Veteran as Vice President of Regulatory Affairs
08:01am, Wednesday, 15'th Jan 2025
New hire set to drive clinical development and U.S. commercialization of the continuous blood glucose monitor for people with diabetes New hire set to drive clinical development and U.S. commercializa
Glucotrack to Present at TechBio Showcase™ 2025
04:05pm, Tuesday, 07'th Jan 2025
Presentation to feature an update on the Company's novel continuous blood glucose monitor for patients with diabetes Presentation to feature an update on the Company's novel continuous blood glucose m
GLUCOTRACK ANNOUNCES START OF ENROLLMENT FOR HUMAN CLINICAL STUDY OF CONTINUOUS BLOOD GLUCOSE MONITOR
08:30am, Tuesday, 03'rd Dec 2024
Feasibility study underway for the Company's novel continuous blood glucose monitor in patients with diabetes, with data expected within 6-8 weeks
Glucotrack, Inc. Announces Closing of $10.0 Million Public Offering and Concurrent Private Placement Converting $4.0 in Outstanding Debt
04:30pm, Thursday, 14'th Nov 2024
Rutherford, NJ., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical technology company focused on the design, development, and commercialization of novel technologies for peo
GLUCOTRACK TO PRESENT AT 2024 BIOFUTURE CONFERENCE
09:00am, Tuesday, 22'nd Oct 2024
Continuous blood glucose monitor to be among 100+ future-focused presentations at industry investor conference Rutherford, NJ, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glu
